Human immunodeficiency virus (HIV) infection is associated with psychiatric complications, including cognitive impairment, affective disorders, and psychosis. These psychiatric complications impair quality of life, affect disease prognosis, and impede treatment by compromising medication adherence. They also increase the likelihood of HIV transmission, either directly or via their high prevalence rate among drug abusers. In this article, the authors provide a brief overview of the most common psychiatric complications associated with HIV infection and discuss the role of dopamine as a link between psychiatric manifestations and the progression of immunodeficiency infection.
Introduction
A large percentage of human immunodeficiency virus (HIV)-positive patients develop a central nervous system (CNS) disorder with neurological and psychiatric symptomatology, referred to as HIVassociated dementia. Prominent clinical CNS manifestation occurs in approximately 30% of patients with acquired immunodeficiency syndrome (AIDS) (Price et al, 1988) , whereas at autopsy a greater proportion of infected individuals exhibit CNS lesions (Gray et al, 1988; Petito, 1988) .
The highly active antiretroviral therapy (HAART) suppresses HIV replication, resulting in improved survival and a reduction in the incidence rate of HIV-associated dementia by approximately one-half (Michaels et al, 1998; Moore and Chaisson, 1999) . Despite the apparent effectiveness of this treatment, the poor penetration of the blood-brain barrier by antiviral agents, the failure of some drug regimens to control virus replication in infected individuals, and the development of resistant viruses make the CNS vulnerable to HIV-induced damage. As recent advances in treatment have increased, the number of people with CNS signs is expected to rise, emphasizing the need to understand CNS disorders associated with HIV infection. Neurological complications and cognitive impairment in HIV disease have been well characterized but psychiatric changes associated with HIV infection have not received the same attention. This may have resulted from the fact that psychiatric illnesses in HIV infection are often overlooked or wrongly interpreted as reactive psychological changes. Psychiatric disorders associated with HIV infection are an important part of the disease as they influence treatment compliance, and thus the efficacy of antiretroviral therapy, as well as the risk behaviour of HIV-infected patients.
This article briefly overviews the most common neuropsychiatric complications associated with HIV infection, cognitive impairment and HIV-related mood and psychotic disorders, and discusses how they may be neurochemically linked with HIVassociated dementia.
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Psychiatric disorders in HIV infection
The prevalence of psychiatric disorders in HIVinfected patients ranges widely, depending on the infected risk group, criteria for evaluation, and stage of HIV disease. HIV is not associated with specific psychiatric symptomatology despite initial reports of a characteristic AIDS lethargy disorder (Diederich et al, 1988) . The differential diagnosis includes psychiatric symptoms of HIV encephalopathy, psychoreactive disorders, or due to opportunistic CNS infections and tumors.
Cognitive impairment
The severity of cognitive alterations in HIV infection range from mild cognitive deficits to severe dementia (Navia et al, 1986) . Profound dysfunction may occur in the late stages of HIV infection (McArthur et al, 1989) , although subtle neuropsychological deficits have been reported in HIV-positive patients in the absence of immunosuppression (Grant et al, 1995) . As cognitive impairment associated with HIV infection has been analyzed in detail, it is not our aim to repeat this information. Instead, we would like to present biochemical data from our own laboratory demonstrating that cognition may be impaired very early following infection. Using the simian immunodeficiency virus (SIV)-macaque model, we found a dramatic reduction in cholinergic neurotransmission in hippocampus within 2 months of infection (Koutsilieri et al, 2000) . The activity of choline acetyltransferase, presently one of the most used estimates of cognitive dysfunction, was significantly reduced. The cholinergic decline was not correlated with viral load or CNS pathological lesions, indicating rather a deficit related to global immunological or neurochemical changes (Koutsilieri et al, 2000) .
Psychotic disorders
Prevalence of new onset psychosis in HIV-infected patients ranges from 0.5% to 15% (Sewell et al, 1994) and seroprevalence studies of patients with psychoses have shown 5-20% to be HIV positive (Cournos et al, 1991; Susser et al, 1993; Stefan and Catalan, 1995) . It appears that psychosis in HIV patients is associated with a higher mortality rate than that in HIV patients without psychotic symptoms (Sewell et al, 1994) . To our knowledge, there are no available data that address the relationship between psychosis and the associated HIV disease progression. Furthermore, it is not clear whether new-onset psychosis is related to the dementing processes or mood deterioration.
The presence of a psychotic disorder prior to HIV infection can increase the risk of infection (Cournos et al, 1991) , presumably because of high-risk behaviors (Kelly et al, 1992) . On the other hand, reports have described new-onset psychosis in the presence of antecedent HIV infection, suggesting that HIV infection induces psychosis (Thomas and Szabadi, 1987; Gabel et al, 1986; Sewell et al, 1994; Harris et al, 1991) . It is noteworthy that psychosis that develops following HIV infection may not be associated with encephalopathy (Susser et al, 1997) . These findings suggest that neurochemical changes directly related to the virus or indirectly via infected cells may lead to psychosis without the involvement of an HIV encephalopathy. Additionally, other factors may predispose (Susser et al, 1997) individuals to both psychotic disorders and HIV infection. Substance abuse could be such a factor (Tsuang et al, 1982) .
Affective disorders
Depression in HIV-infected individuals has been found to range from 15% to 40% (Brown et al, 1992; Treisman et al, 1998; Atkinson et al, 1988) , a proportional prevalence significantly higher than that in general population (Blazer et al, 1994; Kessler et al, 1994) . Depression may alter the course of HIV infection by impairing immune function or influencing behavior. There is evidence that depression is a risk factor for HIV (McDermott et al, 1994) , but depression is also a risk factor for increased substance abuse, which may lead to an enhaced risk of HIV infection (Regier et al, 1990) and is associated with a higher mortality rate (Wilkie et al, 1998; Ickovics et al, 2001) .
With regard to treatment of HIV infection, depression has a profound impact on adherence (Singh et al, 1996) . Depressed patients exhibit a decreased interest in their safety and may ignore medical advice. Subjects adhering to HAART, however, exhibit a lower prevalence of depressive symptoms (Starace et al, 2002) .
Manic syndromes affect approximately 8% of HIVinfected individuals with immunosuppression without a personal or family history of bipolar disorder (Lyketsos et al, 1993) and mostly appear in late stages of HIV disease. These syndromes are usually referred to as "AIDS mania," and are clinically different from classical mania in symptomatology, disease progression, and treatment (Lyketsos et al, 1997; Ellen et al, 1999) . So far, it is unclear whether AIDS mania is a distinct clinical entity or part of the spectrum of HIV dementia, as the development of manic symptoms post infection is often associated with profound cognitive deficits (Lyketsos et al, 1993; McDaniel et al, 1997) . The treatment for patients with AIDS mania is particularly difficult. They do not respond well to mood stabilizers, which usually results in delirium. The administration of low-dose antipsychotics has been more efficient (Angelino and Treisman, 2001 ).
The role of dopamine as a link between HIV infection and psychiatric complications
One of the factors predictive of which group of HIV-infected individuals is most susceptible to psychiatric complications is substance abuse (Basso and Bornstein, 2000) . Drug abuse prevalence in infected individuals is high. Studies reported rates as high as 75% of HIV-positive patients use illicit drugs (Rosenberger et al, 1993; Lyketsos et al, 1994 ) and a higher incidence of HIV encephalopathy in users of addictive drugs compared to other HIV-infected individuals (Martinez et al, 1995; Bell et al, 1996) . It has been postulated that drugs accelerate HIV encephalopathy progression (Pillai et al, 1991; Tyor and Middaugh, 1999; Kibayashi et al, 1996; Phillips et al, 2000) . These substances preferentially activate the mesocortical/mesolimbic dopaminergic pathway (Di Chiara and Imperato, 1988) and can induce a psychosis virtually indistinguishable from schizophrenia. The association of drug abuse with psychiatric disorders is high. Nearly half of the infected individuals screening positive for a psychiatric disorder reported the use of illicit drugs (Bing et al, 2001) .
Psychiatric disorders, similar to drug action and addiction, are associated with dopaminergic systems. An overactivity of the same dopaminergic pathways mediates the positive symptomatology of psychosis, whereas the blockade of dopaminergic neurotransmission by antipsychotic drugs reduces psychotic signs. Neuroleptics are effective for the treatment of psychotic symptoms in HIV infection, although a reduced dose is advisable as even mild dopamine antagonism can result in extrapyramidal side effects (Hriso et al, 1991) . The potential for HIV-infected patients to develop parkinsonian symptomatology following dopamine blocking agents is two-to fourfold greater than that of uninfected psychotic individuals (Hriso et al, 1991) , indicating a great vulnerability of dopaminergic systems in HIV-infected patients.
Newer evidence suggests that increased dopamine availability may affect the progression of immunod-
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Angelino AF, Treisman GJ (2001 Koutsilieri et al, 2002; Nath et al, 2000) . Our group showed that selegiline, a substance that increases dopamine availability, and L-DOPA, the precursor of dopamine, caused marked degenerative CNS changes and accelerated viral infection in SIV-macaques (Czub et al, 2001) . The safety of dopaminergic drugs in the clinical management of HIV-infected patients should therefore be reconsidered, particularly as psychostimulants, antidepressants, and antiparkinsonian agents, all substances that increase dopaminergic availability, are currently advocated to attenuate associated psychiatric symptoms.
Concluding remarks
As patients live longer under HAART, the number of HIV-infected persons with psychiatric disorders may increase. The recognition of psychiatric disorders in HIV clinics is an issue of supreme importance. It is time that psychiatric services realize that HIV may be a new cause of psychiatric manifestations. Early identification of the spectrum of psychiatric disorders attributable to the direct neuropathic effects of HIV, and the development of effective and appropriate treatment strategies, are required. Dopamine appear to be implicated in the pathogenesis of HIV-associated dementia, the effects of substance abuse, and the generation of psychiatric disorders and may be the key factor linking these probably independent processes. Research focusing on dopaminergic regulation in HIV-associated dementia and in related CNS disorders is required to clarify the exact role of this neurotransmitter in HIV infection.
